Browse News
Filter News
Found 350 articles
-
Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation
4/3/2024
Ampio Pharmaceuticals, Inc. announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern.
-
Ampio Announces Voluntary Delisting and SEC Deregistration
3/25/2024
Ampio Pharmaceuticals, Inc. announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended.
-
Ampio Provides Update on Results from Pre-IND Enabling Studies
2/14/2024
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity.
-
Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201
10/5/2023
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company) today announced that it has selected Ascendia Pharmaceuticals, Inc. ("Ascendia") to provide services to support the clinical development of OA-201, a novel therapeutic for the treatment of symptomatic osteoarthritis pain.
-
Ampio Pharmaceuticals to Present at the Emerging Growth Conference
9/26/2023
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") a pre-revenue stage biopharmaceutical Company focused on development of a potential treatment for osteoarthritis as part of its OA.201 program, today announced that its CEO, Michael A. Martino will present in the Emerging Growth Conference on Thursday, October 5, 2023 at 3:25 pm ET.
-
Ampio Pharmaceuticals Announces Reverse Stock Split
8/31/2023
Ampio Pharmaceuticals, Inc. announced that its Board of Directors has approved a 20-to-1 reverse stock split of the Company's common stock.
-
Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock
5/26/2023
Ampio Pharmaceuticals, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on June 8, 2023.
-
Ampio Pharmaceuticals Issues Letter to Stockholders - April 18, 2023
4/18/2023
Ampio Pharmaceuticals, Inc. released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.
-
AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS - January 17, 2023
1/17/2023
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.
-
Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
12/27/2022
Ampio Pharmaceuticals, Inc. announced that it has received notification from The NYSE American LLC stating that the Company has regained compliance with the NYSE American's continued listing standards.
-
Investors who lost Money with shares of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) should contact the Shareholders Foundation in connection with the Lawsuit against Ampio Pharmaceuticals, Inc.
11/29/2022
The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE).
-
Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension
11/17/2022
Ampio Pharmaceuticals, Inc. received notification from NYSE American LLC stating that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the Company's common stock on the NYSE American.
-
Ampio Pharmaceuticals Announces Fifteen-to-One Reverse Stock Split - November 08, 2022
11/8/2022
Ampio Pharmaceuticals, Inc., announced that effective November 9, 2022 at 4:01 p.m. Eastern Time, the Company will amend its certificate of incorporation to implement a fifteen-to-one reverse stock split.
-
Ampio Pharmaceuticals Issues Letter to Stockholders - October 14, 2022
10/14/2022
Ampio Pharmaceuticals, Inc., released the following letter to stockholders from its Chairman, Kevin Buchi, and Chief Executive Officer, Mike Martino.
-
Ampio Pharmaceuticals Issues Letter to Stockholders - October 04, 2022
10/4/2022
Ampio Pharmaceuticals, Inc., released the following letter to stockholders from its Chairman, Kevin Buchi, and Chief Executive Officer, Mike Martino.
-
Ampio Pharmaceuticals Announces NYSE American Has Commenced Delisting Proceedings
10/4/2022
Ampio Pharmaceuticals, Inc. received written notification from NYSE American LLC stating that the staff of NYSE Regulation has determined to commence proceedings to delist the Company's common stock from the Exchange.
-
Ampio Pharmaceuticals Issues Letter to Stockholders
8/3/2022
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.
-
Diabetic Retinopathy Market Insights, Future Trends, On-going Demand, Opportunities, Segmentation, and Forecast Till 2028
5/23/2022
Rising prevalence of diabetes and increasing incidences of blindness among people with severe diabetic conditions are expected to fuel the global market growth
-
Ampio Pharmaceuticals Reports First-Quarter 2022 Financial Results
5/16/2022
Ampio Pharmaceuticals, Inc., a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, reported financial results for the first quarter ended March 31, 2022.
-
Ampio shares continue to fall following the company’s announcement that the FDA rejected proposed changes to a Phase III study of its treatment for osteoarthritis of the knee and other joints.